MedTrace Logo

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

NCT00573326 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-09-03

No results posted yet for this study

Summary

The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.

Conditions

Interventions

DRUG

Imatinib

200 mg p.o. once a day for 6 months

Sponsors & Collaborators

  • Università Politecnica delle Marche

    collaborator OTHER

  • Azienda Ospedaliera Universitaria Policlinico

    lead OTHER

Principal Investigators

  • Armando Gabrielli, MD · Università Politecnica delle Marche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573326 on ClinicalTrials.gov